University of Illinois Cancer Center: Summer CME SeriesSession 3 - Hematologic Malignancies | June 25, 2025Pre-Test UICMES | Session 3 | Pre-Test | June 25, 2025 Name * Name First First Last Last Email * 1. CAR T-cell therapy is currently approved for which hematologic malignancy following ≥2 lines of prior therapy? * A. Chronic myeloid leukemia B. Follicular lymphoma C. Diffuse large B-cell lymphoma D. Polycythemia vera 2. Which is a major advantage of incorporating MRD testing in multiple myeloma treatment planning? * A. It eliminates the need for imaging B. It ensures financial reimbursement C. It guides long-term treatment decisions and relapse risk D. It replaces bone marrow biopsies 3. In relapsed/refractory AML, triplet regimens often include a hypomethylating agent, venetoclax, and: * A. Cytarabine B. Midostaurin C. Gilteritinib D. Azacitidine 4. BCMA-targeted therapies, such as belantamab mafodotin or CAR T-cells, are most effective in: * A. Treatment-naïve multiple myeloma B. Relapsed/refractory multiple myeloma C. MGUS D. Smoldering myeloma 5. (Patient Case). A 68-year-old male with triple-class refractory multiple myeloma previously treated with daratumumab, lenalidomide, and bortezomib is now under consideration for a BCMA-targeted approach. Recent labs show adequate marrow reserve and no active infection. Which treatment offers the most benefit based on recent data? * A. Repeat daratumumab B. Belantamab mafodotin C. CAR T-cell therapy D. Autologous transplant Submit Pre-Test
